{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-164015","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.912935+00:00","generated_at":"2026-06-01T03:22:49.021879+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility","bullets":["Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.","Hazard ratio of 0.65 for OS, stable from 0.59 at primary analysis 10 months earlier.","20/40 amezalpat patients remain in survival follow-up vs 9/30 control.","Entered new Open Market Sale Agreement to sell up to $205M of common stock.","Tempest retains all product rights; data supports potential pivotal Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-164015","json":"https://secwatch.observer/filing/0001193125-24-164015.json","markdown":"https://secwatch.observer/filing/0001193125-24-164015.md","text":"https://secwatch.observer/filing/0001193125-24-164015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/0001193125-24-164015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/d857887d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:22:49.021879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}